Iovance Biotherapeutics Stock Today
| IOVA Stock | USD 11.72 0.08 0.68% |
Performance9 of 100
| Odds Of DistressLess than 9
|
Iovance Biotherapeutics is trading at 11.72 as of the 19th of April 2024, a -0.68 percent decrease since the beginning of the trading day. The stock's open price was 11.8. Iovance Biotherapeutics has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Iovance Biotherapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of April 2023 and ending today, the 19th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of October 2010 | Category Healthcare | Classification Health Care |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patients immune system to eradicate cancer cells. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. The company has 279.31 M outstanding shares of which 46.38 M shares are currently shorted by private and institutional investors with about 5.58 trading days to cover. More on Iovance Biotherapeutics
Moving together with Iovance Stock
| 0.69 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.77 | JSPRW | Jasper Therapeutics | PairCorr |
Moving against Iovance Stock
| 0.55 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Iovance Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Iovance Biotherapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Iovance Biotherapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Maria Fardis | |||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Iovance Biotherapeutics report their recommendations after researching Iovance Biotherapeutics' financial statements, talking to executives and customers, or listening in on Iovance Biotherapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Iovance Biotherapeutics. The Iovance consensus assessment is calculated by taking the average forecast from all of the analysts covering Iovance Biotherapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Iovance Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Iovance Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Iovance Biotherapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Iovance Biotherapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Iovance Biotherapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Iovance Biotherapeutics' financial leverage. It provides some insight into what part of Iovance Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Iovance Biotherapeutics (IOVA) is traded on NASDAQ Exchange in USA. It is located in 825 Industrial Road, San Carlos, CA, United States, 94070 and employs 557 people. Iovance Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Iovance Biotherapeutics's market, we take the total number of its shares issued and multiply it by Iovance Biotherapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Iovance Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 279.31 M outstanding shares of which 46.38 M shares are currently shorted by private and institutional investors with about 5.58 trading days to cover.
Iovance Biotherapeutics currently holds about 424.46 M in cash with (361.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69.
Check Iovance Biotherapeutics Probability Of Bankruptcy
Ownership AllocationIovance Biotherapeutics secures a total of 279.31 Million outstanding shares. The majority of Iovance Biotherapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Iovance Biotherapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Iovance Biotherapeutics. Please pay attention to any change in the institutional holdings of Iovance Biotherapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Iovance Ownership Details
Iovance Stock Price Odds Analysis
What are Iovance Biotherapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Iovance Biotherapeutics jumping above the current price in 90 days from now is about 56.86%. The Iovance Biotherapeutics probability density function shows the probability of Iovance Biotherapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.0148. This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Iovance Biotherapeutics will likely underperform. Additionally, iovance Biotherapeutics has an alpha of 0.5261, implying that it can generate a 0.53 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Iovance Biotherapeutics to move above the current price in 90 days from now is about 56.86 (This Iovance Biotherapeutics probability density function shows the probability of Iovance Stock to fall within a particular range of prices over 90 days) .
Iovance Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Iovance Biotherapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Iovance Biotherapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Iovance Biotherapeutics' value.| Instituion | Recorded On | Shares | |
| Balyasny Asset Management Llc | 2023-12-31 | 3.9 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 3.7 M | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 3.5 M | |
| Mpm Oncology Impact Management Lp | 2023-12-31 | 3.3 M | |
| T. Rowe Price Associates, Inc. | 2023-12-31 | 3.3 M | |
| Jpmorgan Chase & Co | 2023-12-31 | 2.8 M | |
| Credit Suisse First Boston (csfb) | 2023-12-31 | 2.8 M | |
| Principal Financial Group Inc | 2023-12-31 | 2.6 M | |
| Northern Trust Corp | 2023-12-31 | 2.2 M | |
| Vanguard Group Inc | 2023-12-31 | 22.8 M | |
| Mhr Fund Management Llc | 2023-12-31 | 20 M |
Iovance Biotherapeutics Historical Income Statement
Iovance Biotherapeutics Income Statement is one of the three primary financial statements used for reporting Iovance's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Iovance Biotherapeutics revenue and expense. Iovance Biotherapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Iovance Biotherapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 3.6 M, whereas Operating Income is projected to grow to (437.5 M). View More FundamentalsIovance Stock Against Markets
Picking the right benchmark for Iovance Biotherapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Iovance Biotherapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Iovance Biotherapeutics is critical whether you are bullish or bearish towards Iovance Biotherapeutics at a given time. Please also check how Iovance Biotherapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Iovance Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Iovance Biotherapeutics Corporate Directors
Iovance Biotherapeutics corporate directors refer to members of an Iovance Biotherapeutics board of directors. The board of directors generally takes responsibility for the Iovance Biotherapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Iovance Biotherapeutics' board members must vote for the resolution. The Iovance Biotherapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Michael Weiser | Independent Director | Profile | |
| Sanford Hillsberg | Independent Director | Profile | |
| Wayne Rothbaum | Independent Director | Profile | |
| Merrill McPeak | Independent Director | Profile |
How to buy Iovance Stock?
Before investing in Iovance Biotherapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Iovance Biotherapeutics. To buy Iovance Biotherapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Iovance Biotherapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Iovance Biotherapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Iovance Biotherapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Iovance Biotherapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Iovance Biotherapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Iovance Stock please use our How to Invest in Iovance Biotherapeutics guide.
Already Invested in Iovance Biotherapeutics?
The danger of trading Iovance Biotherapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Iovance Biotherapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Iovance Biotherapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Iovance Biotherapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Iovance Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Iovance Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Iovance Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Iovance Biotherapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iovance Biotherapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For information on how to trade Iovance Stock refer to our How to Trade Iovance Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Iovance Stock analysis
When running Iovance Biotherapeutics' price analysis, check to measure Iovance Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iovance Biotherapeutics is operating at the current time. Most of Iovance Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Iovance Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iovance Biotherapeutics' price. Additionally, you may evaluate how the addition of Iovance Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| CEOs Directory Screen CEOs from public companies around the world |
Is Iovance Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iovance Biotherapeutics. If investors know Iovance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iovance Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Revenue Per Share 0.005 | Return On Assets (0.40) | Return On Equity (0.82) |
The market value of Iovance Biotherapeutics is measured differently than its book value, which is the value of Iovance that is recorded on the company's balance sheet. Investors also form their own opinion of Iovance Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iovance Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iovance Biotherapeutics' market value can be influenced by many factors that don't directly affect Iovance Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iovance Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iovance Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iovance Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.